Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03616821 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
242
Enrollment
INDUSTRY
Sponsor class

Stopped Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.

Conditions

Interventions

Sponsor

AstraZeneca